Mometasone

Profil Farmakokinetik

Waktu Paruh (Half-Life) 5.8 hours

Volume Distribusi -

Klirens (Clearance) -

Absorpsi

Nasal spray is virtually undetectable in plasma

Metabolisme

Hepatic. Extensive metabolism to multiple metabolites. There are no major metabolites detectable in plasma. Upon in vitro incubation, one of the minor metabolites formed is 6ß-hydroxy-mometasone furoate. In human liver microsomes, the formation of the metabolite is regulated by cytochrome P-450 3A4.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

1148 Data

Denosumab	The risk or severity of adverse effects can be increased when Denosumab is combined with Mometasone.
Etanercept	The risk or severity of adverse effects can be increased when Etanercept is combined with Mometasone.
Peginterferon alfa-2a	The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Mometasone.
Interferon alfa-n1	The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Mometasone.
Interferon alfa-n3	The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Mometasone.
Peginterferon alfa-2b	The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Mometasone.
Anakinra	The risk or severity of adverse effects can be increased when Anakinra is combined with Mometasone.
Interferon gamma-1b	The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Mometasone.
Interferon alfa-2a	The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Mometasone.
Adalimumab	The risk or severity of adverse effects can be increased when Adalimumab is combined with Mometasone.
Gemtuzumab ozogamicin	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mometasone.
Pegaspargase	The serum concentration of Mometasone can be increased when it is combined with Pegaspargase.
Infliximab	The risk or severity of adverse effects can be increased when Infliximab is combined with Mometasone.
Interferon beta-1b	The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Mometasone.
Interferon alfacon-1	The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Mometasone.
Rituximab	The risk or severity of adverse effects can be increased when Rituximab is combined with Mometasone.
Basiliximab	The risk or severity of adverse effects can be increased when Basiliximab is combined with Mometasone.
Muromonab	The risk or severity of adverse effects can be increased when Muromonab is combined with Mometasone.
Ibritumomab tiuxetan	The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mometasone.
Tositumomab	The risk or severity of adverse effects can be increased when Tositumomab is combined with Mometasone.
Alemtuzumab	The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Mometasone.
Alefacept	The risk or severity of adverse effects can be increased when Alefacept is combined with Mometasone.
Efalizumab	The risk or severity of adverse effects can be increased when Efalizumab is combined with Mometasone.
Antithymocyte immunoglobulin (rabbit)	The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Mometasone.
Interferon alfa-2b	The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Mometasone.
Daclizumab	The risk or severity of adverse effects can be increased when Daclizumab is combined with Mometasone.
Phenylalanine	The risk or severity of adverse effects can be increased when Phenylalanine is combined with Mometasone.
Flunisolide	The risk or severity of adverse effects can be increased when Flunisolide is combined with Mometasone.
Cladribine	Mometasone may increase the immunosuppressive activities of Cladribine.
Carmustine	The risk or severity of adverse effects can be increased when Carmustine is combined with Mometasone.
Amsacrine	The risk or severity of adverse effects can be increased when Amsacrine is combined with Mometasone.
Bleomycin	The risk or severity of adverse effects can be increased when Bleomycin is combined with Mometasone.
Chlorambucil	The risk or severity of adverse effects can be increased when Chlorambucil is combined with Mometasone.
Raltitrexed	The risk or severity of adverse effects can be increased when Raltitrexed is combined with Mometasone.
Mitomycin	The risk or severity of adverse effects can be increased when Mitomycin is combined with Mometasone.
Bexarotene	The risk or severity of adverse effects can be increased when Bexarotene is combined with Mometasone.
Floxuridine	The risk or severity of adverse effects can be increased when Floxuridine is combined with Mometasone.
Tioguanine	The risk or severity of adverse effects can be increased when Tioguanine is combined with Mometasone.
Dexrazoxane	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Mometasone.
Beclomethasone dipropionate	The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Mometasone.
Streptozocin	The risk or severity of adverse effects can be increased when Streptozocin is combined with Mometasone.
Trifluridine	The risk or severity of adverse effects can be increased when Trifluridine is combined with Mometasone.
Gemcitabine	The risk or severity of adverse effects can be increased when Gemcitabine is combined with Mometasone.
Betamethasone	The risk or severity of adverse effects can be increased when Betamethasone is combined with Mometasone.
Epirubicin	The risk or severity of adverse effects can be increased when Epirubicin is combined with Mometasone.
Chloramphenicol	The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Mometasone.
Lenalidomide	The risk or severity of adverse effects can be increased when Lenalidomide is combined with Mometasone.
Altretamine	The risk or severity of adverse effects can be increased when Altretamine is combined with Mometasone.
Zidovudine	The risk or severity of adverse effects can be increased when Zidovudine is combined with Mometasone.
Oxaliplatin	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Mometasone.
Desoximetasone	The risk or severity of adverse effects can be increased when Desoximetasone is combined with Mometasone.
Propylthiouracil	The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Mometasone.
Pentostatin	The risk or severity of adverse effects can be increased when Pentostatin is combined with Mometasone.
Fluticasone propionate	The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Mometasone.
Fluocinolone acetonide	The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Mometasone.
Linezolid	The risk or severity of adverse effects can be increased when Linezolid is combined with Mometasone.
Triamcinolone	The risk or severity of adverse effects can be increased when Triamcinolone is combined with Mometasone.
Clofarabine	The risk or severity of adverse effects can be increased when Clofarabine is combined with Mometasone.
Prednisone	The risk or severity of adverse effects can be increased when Prednisone is combined with Mometasone.
Pemetrexed	The risk or severity of adverse effects can be increased when Pemetrexed is combined with Mometasone.
Fludrocortisone	The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Mometasone.
Mycophenolate mofetil	The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Mometasone.
Daunorubicin	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Mometasone.
Tretinoin	The metabolism of Tretinoin can be increased when combined with Mometasone.
Methimazole	The risk or severity of adverse effects can be increased when Methimazole is combined with Mometasone.
Dacarbazine	The risk or severity of adverse effects can be increased when Mometasone is combined with Dacarbazine.
Temozolomide	The risk or severity of adverse effects can be increased when Mometasone is combined with Temozolomide.
Penicillamine	The risk or severity of adverse effects can be increased when Mometasone is combined with Penicillamine.
Prednisolone	The risk or severity of adverse effects can be increased when Mometasone is combined with Prednisolone.
Azacitidine	The risk or severity of adverse effects can be increased when Mometasone is combined with Azacitidine.
Carboplatin	The risk or severity of adverse effects can be increased when Mometasone is combined with Carboplatin.
Methylprednisolone	The risk or severity of adverse effects can be increased when Mometasone is combined with Methylprednisolone.
Dactinomycin	The risk or severity of adverse effects can be increased when Mometasone is combined with Dactinomycin.
Cytarabine	The risk or severity of adverse effects can be increased when Mometasone is combined with Cytarabine.
Azathioprine	The risk or severity of adverse effects can be increased when Mometasone is combined with Azathioprine.
Hydroxyurea	The risk or severity of adverse effects can be increased when Mometasone is combined with Hydroxyurea.
Clobetasol propionate	The risk or severity of adverse effects can be increased when Mometasone is combined with Clobetasol propionate.
Mycophenolic acid	The risk or severity of adverse effects can be increased when Mometasone is combined with Mycophenolic acid.
Topotecan	The risk or severity of adverse effects can be increased when Mometasone is combined with Topotecan.
Mercaptopurine	The risk or severity of adverse effects can be increased when Mometasone is combined with Mercaptopurine.
Thalidomide	The risk or severity of adverse effects can be increased when Mometasone is combined with Thalidomide.
Melphalan	The risk or severity of adverse effects can be increased when Mometasone is combined with Melphalan.
Fluocinonide	The risk or severity of adverse effects can be increased when Mometasone is combined with Fluocinonide.
Fludarabine	The risk or severity of adverse effects can be increased when Mometasone is combined with Fludarabine.
Flucytosine	The risk or severity of adverse effects can be increased when Mometasone is combined with Flucytosine.
Capecitabine	The risk or severity of adverse effects can be increased when Mometasone is combined with Capecitabine.
Procarbazine	The risk or severity of adverse effects can be increased when Mometasone is combined with Procarbazine.
Arsenic trioxide	The risk or severity of adverse effects can be increased when Mometasone is combined with Arsenic trioxide.
Idarubicin	The risk or severity of adverse effects can be increased when Mometasone is combined with Idarubicin.
Estramustine	The risk or severity of adverse effects can be increased when Mometasone is combined with Estramustine.
Mitoxantrone	The risk or severity of adverse effects can be increased when Mometasone is combined with Mitoxantrone.
Lomustine	The risk or severity of adverse effects can be increased when Mometasone is combined with Lomustine.
Budesonide	The risk or severity of adverse effects can be increased when Mometasone is combined with Budesonide.
Dexamethasone	The risk or severity of adverse effects can be increased when Mometasone is combined with Dexamethasone.
Eculizumab	The risk or severity of adverse effects can be increased when Mometasone is combined with Eculizumab.
Decitabine	The risk or severity of adverse effects can be increased when Mometasone is combined with Decitabine.
Nelarabine	The risk or severity of adverse effects can be increased when Mometasone is combined with Nelarabine.
Abatacept	The risk or severity of adverse effects can be increased when Mometasone is combined with Abatacept.
Corticotropin	The risk or severity of adverse effects can be increased when Mometasone is combined with Corticotropin.
Cortisone acetate	The risk or severity of adverse effects can be increased when Mometasone is combined with Cortisone acetate.

Target Protein

Glucocorticoid receptor NR3C1

Progesterone receptor PGR

Referensi & Sumber

Synthesis reference: Pui-Ho Yuen, Charles Eckhart, Teresa Etlinger, Nancy Levine, "Mometasone furoate monohydrate, process for making same and pharmaceutical compositions." U.S. Patent US6127353, issued April, 1988.

Contoh Produk & Brand

Produk: 0 • International brands: 0

Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.

Peringatan Keamanan

Deskripsi

Struktur Molekul 2D

Deskripsi metode visualisasi

1. Pendahuluan & Konsep

2. Sumber Data (Validasi)

3. Algoritma Visualisasi

4. Legenda Visual